RTS,S/AS02A Malaria Vaccine Does Not Induce Parasite CSP T Cell Epitope Selection and Reduces Multiplicity of Infection
Open Access
- 19 May 2006
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Clinical Trials
- Vol. 1 (1) , e5
- https://doi.org/10.1371/journal.pctr.0010005
Abstract
The candidate malaria vaccine RTS,S/AS02A is a recombinant protein containing part of the circumsporozoite protein (CSP) sequence of Plasmodium falciparum, linked to the hepatitis B surface antigen and formulated in the proprietary adjuvant system AS02A. In a recent trial conducted in children younger than age five in southern Mozambique, the vaccine demonstrated significant and sustained efficacy against both infection and clinical disease. In a follow-up study to the main trial, breakthrough infections identified in the trial were examined to determine whether the distribution of csp sequences was affected by the vaccine and to measure the multiplicity of infecting parasite genotypes. P. falciparum DNA from isolates collected during the trial was used for genotype studies. The main trial was carried out in the Manhiça district, Maputo province, Mozambique, between April 2003 and May 2004. Children from the two cohorts of the main trial provided parasite isolates as follows: children from Cohort 1 who were admitted to hospital with clinical malaria; children from Cohort 1 who were parasite-positive in a cross-sectional survey at study month 8.5; children from Cohort 2 identified as parasite-positive during follow-up by active detection of infection. Divergence of DNA sequence encoding the CSP T cell–epitope region sequence from that of the vaccine sequence was measured in 521 isolates. The number of distinct P. falciparum genotypes was also determined. We found no evidence that parasite genotypes from children in the RTS,S/AS02A arm were more divergent than those receiving control vaccines. For Cohort 1 (survey at study month 8.5) and Cohort 2, infections in the vaccine group contained significantly fewer genotypes than those in the control group, (p = 0.035, p = 0.006), respectively, for the two cohorts. This was not the case for children in Cohort 1 who were admitted to hospital (p = 0.478). RTS,S/AS02A did not select for genotypes encoding divergent T cell epitopes in the C-terminal region of CSP in this trial. In both cohorts, there was a modest reduction in the mean number of parasite genotypes harboured by vaccinated children compared with controls, but only among those with asymptomatic infections. ClinicalTrials.gov NCT00197041Keywords
This publication has 30 references indexed in Scilit:
- Broad Cross-Clade T-Cell Responses to Gag in Individuals Infected with Human Immunodeficiency Virus Type 1 Non-B Clades (A to G): Importance of HLA Anchor Residue ConservationJournal of Virology, 2005
- Vaccines for preventing malariaPublished by Wiley ,2003
- Plasmodium falciparum multiple infections in Mozambique, its relation to other malariological indices and to prospective risk of malaria morbidityTropical Medicine & International Health, 2003
- Analysis of CD4 + T-Cell Responses to Human Papillomavirus (HPV) Type 11 L1 in Healthy Adults Reveals a High Degree of Responsiveness and Cross-Reactivity with Other HPV TypesJournal of Virology, 2002
- A Recombinant Blood‐Stage Malaria Vaccine ReducesPlasmodium falciparumDensity and Exerts Selective Pressure on Parasite Populations in a Phase 1–2b Trial in Papua New GuineaThe Journal of Infectious Diseases, 2002
- Efficacy of Recombinant Circumsporozoite Protein Vaccine Regimens against ExperimentalPlasmodium falciparumMalariaThe Journal of Infectious Diseases, 2001
- Potent Induction of Focused Th1‐Type Cellular and Humoral Immune Responses by RTS,S/SBAS2, a RecombinantPlasmodium falciparumMalaria VaccineThe Journal of Infectious Diseases, 1999
- Complexity ofPlasmodium falciparumInfections Is Consistent over Time and Protects against Clinical Disease in Tanzanian ChildrenThe Journal of Infectious Diseases, 1999
- An efficacy trial of the malaria vaccine SPf66 in Gambian infants—second year of follow-upVaccine, 1998
- A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine againstPlasmodium falciparumMalariaNew England Journal of Medicine, 1997